ATE403424T1 - Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa - Google Patents

Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa

Info

Publication number
ATE403424T1
ATE403424T1 AT06743645T AT06743645T ATE403424T1 AT E403424 T1 ATE403424 T1 AT E403424T1 AT 06743645 T AT06743645 T AT 06743645T AT 06743645 T AT06743645 T AT 06743645T AT E403424 T1 ATE403424 T1 AT E403424T1
Authority
AT
Austria
Prior art keywords
zinc gluconate
treat
hydradenitis suppurativa
hydradenitis
suppurativa
Prior art date
Application number
AT06743645T
Other languages
English (en)
Inventor
Catherine Suck
Brigitte Dreno
Jacques Bodin
Original Assignee
Labcatal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labcatal filed Critical Labcatal
Application granted granted Critical
Publication of ATE403424T1 publication Critical patent/ATE403424T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06743645T 2005-04-13 2006-04-06 Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa ATE403424T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503695A FR2884420B1 (fr) 2005-04-13 2005-04-13 Nouvelle utilisation du gluconate de lithium pour le traitement de l'hidradenite suppuree

Publications (1)

Publication Number Publication Date
ATE403424T1 true ATE403424T1 (de) 2008-08-15

Family

ID=35522612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743645T ATE403424T1 (de) 2005-04-13 2006-04-06 Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa

Country Status (10)

Country Link
US (1) US20090215889A1 (de)
EP (1) EP1874291B1 (de)
AT (1) ATE403424T1 (de)
AU (1) AU2006234397B2 (de)
BR (1) BRPI0610524A2 (de)
CA (1) CA2604028A1 (de)
DE (1) DE602006002126D1 (de)
ES (1) ES2308744T3 (de)
FR (1) FR2884420B1 (de)
WO (1) WO2006108949A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053917A2 (en) * 2009-11-01 2011-05-05 Adeona Pharmaceuticals, Inc. Gastroretentive oral high dose zinc preparations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503070A (en) * 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold
FR2574295B1 (fr) * 1984-12-07 1988-02-26 Rech Etu Therapeutiques Medicaments a base de gluconate de zinc utiles pour le traitement des hyperprolactinemies
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation

Also Published As

Publication number Publication date
WO2006108949A2 (fr) 2006-10-19
CA2604028A1 (fr) 2006-10-19
FR2884420B1 (fr) 2007-07-06
WO2006108949A3 (fr) 2007-03-29
EP1874291B1 (de) 2008-08-06
ES2308744T3 (es) 2008-12-01
FR2884420A1 (fr) 2006-10-20
AU2006234397B2 (en) 2011-04-07
EP1874291A2 (de) 2008-01-09
BRPI0610524A2 (pt) 2016-11-16
US20090215889A1 (en) 2009-08-27
AU2006234397A1 (en) 2006-10-19
DE602006002126D1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
ATE533484T1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60115842D1 (de) Ventilanordnung
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE403424T1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE446759T1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
DE60308862D1 (de) Verbindungen und zusammensetzungen zur behandlung von diabetes und erkrankungen, die mit diabetes in zusammenhang stehen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties